This study is for patients with a type of lung cancer called non-small cell lung cancer (NSCLC) that has a specific change in the EGFR gene. *EGFR* stands for *Epidermal Growth Factor Receptor*, and it helps cells grow. If this gene changes, it might cause cancer to grow faster. The study compares two treatments: Izalontamab Brengitecan (a new drug) and Platinum-Pemetrexed (a standard chemotherapy). To join, patients must have tried and not responded to other EGFR treatments like osimertinib. They should be able to handle chemotherapy with drugs like cisplatin. Importantly, patients cannot have serious health issues or certain types of cancer spread like leptomeningeal metastases.

• Length of Study: This study may require multiple visits over a period of months.
• Treatments Involved: Participants will receive either the new drug or standard chemotherapy.
• Health Monitoring: Regular check-ups will be needed to monitor health and treatment effects.